Literature DB >> 30814350

Diagnostic Approach of Early-Onset Dementia with Negative Family History: Implications from Two Cases of Early-Onset Alzheimer's Disease with De Novo PSEN1 Mutation.

Jia Liu1, Qianqian Wang1, Donglai Jing1, Ran Gao1, Jing Zhang1, Chunlei Cui2, Hongwen Qiao2, Zhigang Liang2, Chaodong Wang1,3, Pedro Rosa-Neto4, Liyong Wu1,3, Jianping Jia1, Serge Gauthier4.   

Abstract

For early-onset Alzheimer's disease (EOAD) cases with unclear family history, most cases are sporadic. Some cases are positive in genetic findings, that is, either incomplete penetrance or de novo mutation. We aimed to focus on EOAD cases with de novo mutations. Case reports and literature review were performed. The implication for diagnostic approach of early-onset dementia with negative family history was developed. We reported two Chinese EOAD cases with de novo mutations. The genotype PSEN1 G206S appeared to correlate with the phenotype of EOAD with pure cognitive problems. The second case had a PSEN1 M233V mutation with an earlier age of onset of 25 with cognitive decline, parkinsonism, and epilepsy. Although EOAD due to de novo mutations is not common, it should be considered in patients with a phenotype of progressive cognitive decline and amyloid positivity on PET or CSF analysis.

Entities:  

Keywords:  De novo PSEN1 mutation; diagnostic approach; early-onset Alzheimer’s disease; early-onset dementia with negative family history

Year:  2019        PMID: 30814350     DOI: 10.3233/JAD-181108

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  2 in total

1.  A heterozygous de novo PSEN1 mutation in a patient with early-onset parkinsonism.

Authors:  Yueting Chen; Peng Liu; Fei Xie; Bo Wang; Zhiru Lin; Wei Luo
Journal:  Neurol Sci       Date:  2021-11-29       Impact factor: 3.307

Review 2.  Amyloid-β: a potential link between epilepsy and cognitive decline.

Authors:  Michele Romoli; Arjune Sen; Lucilla Parnetti; Paolo Calabresi; Cinzia Costa
Journal:  Nat Rev Neurol       Date:  2021-06-11       Impact factor: 42.937

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.